<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167751</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Heart-001</org_study_id>
    <nct_id>NCT01167751</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction</brief_title>
  <official_title>Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the important reasons for human dying is Ischemic heart disease (IHD). The most reason
      is coronary artery disease. Beside morbidity, IHD induce myocardial infarction and necrosis
      which due to congestive heart failure.

      One therapeutic method is cellular cardiomyoplasty, which is to produce and substitute the
      cardiac cells with stem cell transplantation. Cell therapy is a potential therapeutic method
      to prevent ventricular remodeling after acute myocardial infarction. Human and animal studies
      have shown that stem cell trans plantation to myocardial infarcted zone can improve heart
      contractile function.

      The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation
      in patients with myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction at rest, measured by gated SPECT</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional contractility in the AOI / Change in LV dimensions (left ventricular end systolic diameter [LVESD], left ventricular end diastolic diameter [LVEDD]) as assessed by echocardiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in LVM index, LVEDV, LVESV</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>MNC implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BM derived MNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC 133 implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of BM derived AC 133</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of cell carrier</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MNC</intervention_name>
    <description>Implantation of BM derived MNC</description>
    <arm_group_label>MNC implantation</arm_group_label>
    <other_name>MNC injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AC 133</intervention_name>
    <description>Implantation of BM derived AC133</description>
    <arm_group_label>AC 133 implantation</arm_group_label>
    <other_name>AC133 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Injection of cell carrier</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CABG candidate

          -  At least 4 akinetic segments

          -  First anterior heart attack within in 10 days to 3 month.

          -  St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by
             echocardiography.

          -  The target lesion had to be located in the left anterior descending (LAD) section.

        Exclusion Criteria:

          -  History of prior anterior myocardial infarction:

          -  History of prior CABG

          -  Poor echocardiography window.

          -  Active infection or history of recurrent infection or positive test for syphilis
             (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l

          -  Documental terminal illness or malignancy.

          -  Previous bone marrow transplant

          -  Autoimmune disease (e. g Lupus, Multiple sclerosis)

          -  Any contraindication for bone - marrow aspiration.

          -  Positive pregnancy test (in women with child bearing potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammadhassan Nasseri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baghiatollah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
  </link>
  <reference>
    <citation>Ahmadi H, Baharvand H, Ashtiani SK, Soleimani M, Sadeghian H, Ardekani JM, Mehrjerdi NZ, Kouhkan A, Namiri M, Madani-Civi M, Fattahi F, Shahverdi A, Dizaji AV. Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction. Curr Neurovasc Res. 2007 Aug;4(3):153-60.</citation>
    <PMID>17691968</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Bone marrow stem cells</keyword>
  <keyword>AC133</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

